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Inhaled steroids, delivered by metered dose aerosol and dry powder inhalers, have proved effective in reducing the 
need for oral steroids in patients with oral steroid-dependant asthma. This randomized, double-blind study, 
compared the efficacy and tolerability of nebulized fluticasone propionate (FP NebulesTM), 2 mg b.d. (FP 4 mg) and 
0.5 mg b.d. (FP 1 mg) with placebo, on the reduction of oral steroid requirement in 301 adult patients with oral 
steroid-dependent asthma. 
Primary efficacy was assessed by the reduction in daily oral steroid dose. Secondary efficacy parameters included 
daily diary card peak expiratory flow (PEF), day and night-time symptoms and clinic lung function measurements. 
Safety was assessed by adverse event monitoring and serum cortisol levels. 
After 12 weeks of treatment the adjusted mean f SEM reduction in oral prednisolone was significantly greater in 
the FP 4 mg group (444 _+ 0.98 mg day-‘) compared with FP 1 mg (2.16 f 1.00 mg day-‘, P= 0.039) and placebo 
(1.20f 1.02 mg day-‘, P= 0.004). A higher percentage of patients discontinued the use of oral steroids with FP 4 
mg (37%) compared with FP 1 mg (26%, P=O.O38) and placebo (18%, P<O.OOl). Following treatment, the 
adjusted mean morning PEF showed a trend in favour of FP 4 mg (280_+ 4 1 mini) compared with placebo 
(270*5 lmin-‘, P= 0.053) and the evening PEF was significantly higher with FP 4 mg (305 +4 1 mini) compared 
with FP 1 mg (292+4 1 mm-‘, P= 0.010). FP 4 mg resulted in a significantly higher percentage of days when the 
patients were free from daytime (P=O.O36) and night-time (P=O.O21) wheeze, compared with placebo. 
Significantly fewer patients withdrew from the FP 4 mg group compared with the other two groups (vs. FP 
1 mg, P = 0.003; vs. placebo, P= 0.032). All three treatments were well tolerated and the incidence of adverse events 
was similar between the groups. 
FP Nebules at a daily dose of between 1 and 4 mg are a safe and effective means of reducing the oral steroid 
requirement of patients with chronic oral steroid dependent asthma. 
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Introduction 
The introduction of inhaled steroids two decades ago 
allowed many patients with severe chronic asthma to 
substantially reduce or discontinue the oral steroids 
necessary to control their disease (1). Inhaled corticoster- 
oids such as beclomethasone dipropionate (BDP) and 
budesonide are well recognized as important therapies in 
the management of chronic asthma, but there are still 
patients with chronic severe asthma who cannot be 
adequately controlled with inhaled corticosteroids and 
bronchodilators and who, therefore, require maintenance 
treatment with oral steroids (2). Nebulized corticosteroids 
have been used as a means of administering high doses of 
corticosteroids to patients with severe asthma, including 
patients with acute exacerbations (3) and those with oral 
corticosteroid-dependant disease (4). In addition, nebulized 
therapy is of value in patients who have difficulty co- 
ordinating their inhalers, which is more likely to be a 
problem in patients with severe disease. 
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Fluticasone propionate (FP) is a relatively new inhaled 
corticosteroid (5,6), which a number of clinical trials have 
shown to have an improved therapeutic ratio compared 
with other commonly used inhaled corticosteroids (7). Such 
studies have demonstrated that FP is more effective at the 
same daily mg dose (8,9) and at least as or more effective 
at half the dose (7,1&13) of BDP and budesonide. 
Crucially, FP is not appreciably absorbed from the 
gastrointestinal tract and undergoes high first pass meta- 
bolism. resulting in negligible oral bioavailability and hence 
0954-6111/99/100689+11 $12*00/O 0 1999 HARCOURT PUBLISHERS LTD 
690 J. WESTBROEK ETAL. 
reduced potential for systemic effects (5). Its use should 
allow patients with more severe asthma to reduce or 
discontinue their need for oral corticosteroids (14), thus 
minimizing the risk of systemic corticosteroid side effects 
(15). 
Fluticasone propionate has now been formulated in 
NebulesTM for adminis tration by nebulization. Nebuliiers 
provide a convenient means of delivering high doses of 
corticosteroids at low inspiratory flow rates (i.e. using tidal 
breathing) without the need for patients to co-ordinate any 
essential manoeuvres or to hold their breath (16). This 
study was designed to compare the oral corticosteroid 
sparing effect of nebulized FP at two dose levels with 
placebo, over a 3 month period, in patients with chronic 
oral corticosteroid-dependent asthma. 
Patients and methods 
PATIENTS 
A total of 360 male and female patients, aged 17 years or 
over, with an established history of severe chronic asthma 
requiring treatment with oral corticosteroids and ,& agonist 
therapy were enrolled into the study. Patients were required 
to be on continuous oral corticosteroid therapy for at least 
3 months before entry to the study. All were outpatients, 
who in addition to receiving oral corticosteroids at a dose 
of at least 5 mg day-’ (or 10 mg every second day), but no 
more than 30 mg day-’ (or 60 mg every second day), could 
be receiving either no inhaled corticosteroid or up to and 
including 2 mg day-’ inhaled beclomethasone dipropionate 
or budesonide or up to and including 1 mg day -’ inhaled 
FP. In the 2 week run-in phase of the study, patients were 
required to demonstrate either a diurnal variation of at 
least 15% in PEF, or at least 4 days of the run-in period, or 
reversibility in forced expiratory volume in 1s (FEVi) with 
salbutamol of at least 15%. Patients were excluded if they 
had changes in their regular asthma medication (i.e. inhaled 
corticosteroids, oral corticosteroid or other inhaled or oral 
therapies), had an upper or lower respiratory tract infection 
requiring treatment with antibiotics, a hospital admission 
for respiratory disease in the 4 weeks before the run-in 
period, an exacerbation of asthma during the run-in period 
which required additional oral corticosteroid treatment, a 
history or laboratory data indicative of serious clinical 
systemic disease, a serious psychological disorder or any 
disease likely to interfere with the objectives of this study. 
Patients were also excluded if they had any known or 
suspected hypersensitivity to corticosteroids or if they had 
received any other investigational drug within the previous 
4 weeks. Three hundred and one patients were randomized 
to receive treatment; 103 received FP Nebules 2 mg b.d. (FP 
4 mg), 102 received FP Nebules 0.5 mg b.d. (FP 1 mg) and 
96 received placebo Nebules b.d. Fifty nine patients were 
withdrawn before randomization, of which 26 failed to 
meet the entry criteria at the end of the run-in period, 18 
experienced an adverse event during the run-in period, 
fewer were withdrawn for non-compliance and the remain- 
ing 11 were withdrawn because they were unwilling or 
unable to return for all the necessary visits (Fig. 1). 
Regulatory and ethics committee approval was obtained 
for each centre before the start of the study and written 
informed consent was obtained from each patient before 
entry into the study. The study was conducted in 
accordance with the ethical code of practice of the 
declaration of Helsinki. 
STUDY DESIGN 
This was a multicentre, randomized, double-blind, parallel 
group comparison lasting a total of 16 weeks, performed in 
45 centres in 19 countries (i.e. Australia, Austria, Croatia, 
Finland, Iceland, Netherlands, Norway, South Africa, 
Switzerland and the United Kingdom). 
There was a 2-week run-in period during which patients 
remained on their existing does of inhaled and oral 
corticosteroids. Patients were allowed to repeat the run-in 
once if they did not fulfil the entry criteria after the first 
run-in period. Patients satisfying the entry criteria were 
randomized to receive one of three nebulized treatments, 
FP Nebules 2 mg twice daily, FP Nebules 0.5 mg twice daily 
or placebo Nebules twice daily, for a 1Zweek treatment 
period. During this time they continued taking their 
existing inhaled corticosteroid at the same dose and their 
preduisolone tablets at the reducing dose. Patients were also 
issued with VentolinTM (either a metered dose inhaler or 
DiskhalerTM in accordance with their previous experience) 
for use as required, for the relief of symptoms. 
One of the following nebulizer bowl and compressor 
combinations was supplied to each patient together with the 
corresponding tubing and accessories: Sidestream and 
Portaneb 50, Pari LC plus and Pari-Boy or Cirrus and 
DeVilbiss: P&no-Aide. Each centre selected only one 
nebulizer bowl and compressor combination according to 
Iocal preferences and practices. All patients were encour- 
aged to use a mouth-piece with nebulized study medication. 
A face-mask could be used if the patient was unable or 
unwilling to use the mouth-piece. Less than 6% of patients 
used a face-mask in this study. If a face-mask was used, the 
patient was asked to wash his/her face using a barrier cream. 
Treatment randomizations were achieved using a com- 
puterized scheme written in Fortran called ‘Patient Alloca- 
tion for Clinical Trials’ (PACT). A follow-up visit was 
conducted 2 weeks following the completion of the 
treatment period to ensure patient safety. 
METHODS 
Primary efficacy was measured by the reduction in oral 
prednisolone doses achieved by the patients while asthma 
stability was maintained. Investigators were asked to 
document whether the patient had attempted to reduce 
their oral corticosteroid dose in the previous 6 months to 
confnm the patient’s need for the current dose. At each 
fortnightly visit during the treatment period, the investi- 
gator assessed the stability of the patient’s asthma and 
reduced the daily does of oral prednisolone by 2.5 mg (or 
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5 mg on alternate days) each time if the patient’s asthma daily record (diary) card returned at the previous visit and 
was stable relative to his/her normal level of s~ptoms and neither their morning PEF nor their evening PEF had fallen 
lung function (i.e. their symptom score, day or night had by more than 10%). In addition, tbe investigator needed to 
not increased by more than one on three consecutive days, be satisfied that a dose reduction was acceptable to the 
either within the preceding 14 days, or compared with the patient. If a faster dose reduction was approp~ate for the 
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patient, then the daily dose of oral prednisolone could be 
reduced by 5 mg (10 mg if taken on alternate days) each 
time for patients who were taking a daily prednisolone dose 
of greater than 10 mg day-i (20 mg on alternative days), 
after which the dose reduction was by 2.5 mg (5 mg if taken 
on alternate days) once the daily dose had been reduced to 
10 mg day-’ (20 mg on alternate days) or below. 
Additional efficacy assessments were based on daily 
measurement of PEF and daily recording of daytime and 
night-time asthma symptom scores recorded in a diary card 
by the patients and on pulmonary function tests performed 
at each clinic visit. 
IN VITRO NEBULIZER STUDIES 
h vitro testing using a cascade impactor, prior to starting 
the study, demonstrated that the respirable fractions (i.e. 
particle sizes of between 2 u to 6 u, as % of mean content) 
from 2 ml of the 2 mg 2 ml-’ Nebules used according to 
their respective manufacturer’s instructions for the Side- 
stream/Portaneb 50, Pari LC plus/Pari-Boy and Cirrus/ 
DeVilbiss: Pulmo-Aide nebulisers were 14.9%. 11.9% and 
16.2%, respectively. 
ADVERSE EVENTS 
All adverse events were recorded, whether serious or minor 
and irrespective of their causality. Serious adverse events 
were defined as: death, life threatening events, disabling or 
incapacitating events, events which required or prolonged 
hospitalization, a resulting congenital abnormality, cancer, 
drug overdose, and any serious laboratory abnormally that 
was associated with clinical signs or symptoms. 
LABORATORY EVALUATIONS 
Venous blood samples were collected during the clinic visits 
at baseline and after 6 and 12 weeks of treatment for the 
evaluation of haematology and biochemical parameters and 
serum cortisol. Where possible, samples were taken between 
08:OO and 10:00 h. Separate analyses for serum cortisol were 
performed for all samples and for samples collected 
between 08:OO and IO:00 h, as required by the protocol. 
The result obtained for each test parameter was also 
compared to a predefined set of laboratory threshold 
values. The threshold values lie outside the normal range 
(i.e. lower threshold co.67 x lower limit of the normal 
range) and are regarded as potentially important reductions 
or increases in the test parameter. All samples were 
analysed centrally (CORNING Hazleton, Harrogate, 
U.K.) using the TDx CortisolTM fluorescence polarisation 
immunoassay (Abbott Laboratories, Abbott Park, Illinois, 
U.S.A.) 
ANALYSIS 
Statistical analyses were carried out using SAS version 6.08 
(SAS Software Limited, Marlow, U.K.). Hypothesis tests 
looked at all of the pair-wise comparisons between the three 
treatment groups. Treatment differences were assessed 
using two-sided significance tests, based at the 5% 
significance level. For the purpose of analysis, the centres 
were amalgamated into nine clusters according to geogra- 
phical regions, in order to provide adequate patient 
numbers within each group. Based on a standard deviation 
of 8.5 mg day-‘, and a clinical difference between 
treatments of 5 mg day -i in reduction of oral steroid 
usage, then a total of 100 patients per treatment would 
ensure that the study had 80% power in detecting such a 
difference at the 5% significance level. 
The analysis of oral corticosteroid reduction (absolute 
change from start of treatment) was carried out using 
patients’ last available data recorded whilst taking study 
treatment and using analysis of covariance with the dose at 
randomization and age taken as covariates. Variations due 
to country, sex and model of nebulizer were also accounted 
for in the model. Significant two-factor interactions with 
treatment were explored. The assumption of normality 
was not satisfied when analysing oral steroid percent- 
age reduction from start of treatment, therefore the 
Van-Elteren extension to the Wilcoxon rank sum test was 
used, with country as a stratifying variable in the analysis. 
The confidence limits were calculated using an unstratified 
Wilcoxon rank sum test. A weighted mean oral corticoster- 
oid consumption (based on area under the curve) was 
calculated for each patient over the 12 week treatment 
period. Patients not recording a measurement at the end of 
the 12 week treatment period had their last available 
measurement carried forward. The derived weighted mean 
was analysed using analysis of covariance for absolute 
change in oral corticosteroid usage. 
Mean morning PEF, mean evening PEF and mean 
percentage diurnal variation in PEF were derived, with the 
denominator based on the number of days where morning/ 
evening PEF was recorded. Derived PEF values were then 
investigated using analysis of covariance, with the respec- 
tive mean lung function, taken over the final week of run-in, 
and age taken as covariates. Variations due to country, sex 
and model of nebulizer were also accounted for in the 
model. Significant two-factor interactions with treatment 
were explored. The Van Elteren extension to the Wilcoxon 
rank sum test was used to assess pair-wise differences 
between the treatment groups for each symptom variable 
and the use of rescue medication. Serum cortisol values 
were log-transformed prior to analysis and the difference 
between treatments was expressed as a ratio between 
treatments. The latter were analysed using analysis of 
covariance. 
Results 
Patient characteristics at baseline are shown in Table 1. One 
hundred and three patients received FP 2 mg b.d. (FP 4 
mg), 102 received FPO.5 mg b.d. (FP 1 mg) and 96 received 
placebo. The three treatment groups were well-matched 
with respect to demographic characteristics, history of 
asthma, concurrent medication and daily dose of oral 
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TABLE 1. Patient characteristics at baseline 
Characteristic FP 4 mg day-’ FP 1 mg day- ’ 
(2 mg b.d.) (0.5 mg b.d.) 
Placebo 
Patients n 
Sex n (%) 
Males 
Females 
Age n (%) 
16<40 
40-<65 
2 65 
Age range (yrs) 
Duration of asthma n (%) 
l-5 yrs 
6-10yrs 
> 10 yrs 
Tobacco use n (%) 
Never 
Former user 
Current user 
Concurrent medications n (%) 
Inhaled corticosteroid 
Inhaled long-acting /3z-agonist 
Methylxanthines 
Anticholinergics 
Cromoglycate 
Ketotifen 
Other asthma medication 
Oral steroid usage II (%)* 
< 5 mg daily 
5-c 10 mg daily 
1 O- < 20 mg daily 
20-30 mg daily 
103 102 96 
51(50) 58(57) 55(57) 
52(50) 44(43) 41(43) 
17(17) 14(14) 12(13) 
58(56) 54(53) 59(61) 
28(27) 34(33) 25(26) 
19-83 22-78 20-76 
9(9) 24(24) 14(15) 
25(24) 27(26) 21(22) 
69(67) 51(50) 61(64) 
47(46) 43(42) 33(34) 
45(44) 47(46) 52(54) 
ll(11) 12( 12) ll(11) 
89(86) 85(83) 83(86) 
55(23) 47(20) 50(2 1) 
51(22) 49(21) 51(21) 
26(11) 36(15) 42(18) 
8(3) 7(3) 7(3) 
O(O) l(O) O(O) 
6(3) 5(2) 5(2) 
16 1) 0 0 
46(45) 51(50) 38(40) 
45(44) W’) 49(5 1) 
ll(11) 8(13) 9(9) 
FP: fluticasone propionate. 
*approximately 10% of patients took their oral steroid dose on alternate days but the equivalent daily dose is included in the 
table. 
steroid at entry to the study; Between 83% and 86% of 
patients in each treatment group were taking inhaled 
corticosteroids (i.e. FP, beclomethasone dipropionate, 
budesonide, flunisolide) during the 12 weeks of the study. 
The mean * SD daily doses of inhaled corticosteroids in the 
three treatment groups were similar (i.e. 1409k 554 mg 
day-‘(FP 4 mg), 1460+635 mg day-‘(FP 1 mg), 
1389 _+ 649 mg day- ‘(placebo)). 
ORAL PREDNISOLONE REDUCTION 
The results of oral steroid usage are shown in Table 2. At 
randomization, patients in the FP 4 mg group received 
a rneanks~ daily oral prednisolone dose of 10.3 _+ 5.8 mg 
day-‘, which decreased to 5.3k7.5 mg day-’ after 12 
weeks of treatment, a mean reduction of 5.0+ 7.5 mg 
day-‘. Over the same period, patients in the FP 1 mg group 
decreased their mean daily dose from 9.5 4 5.6 mg day-’ to 
6.2k8.1 mg day-‘, a mean reduction of 3.9& 8.3 mg 
day-‘, and the placebo group dose decreased from 
10.3k5.9 mg day-’ to 7.447~8 mg day-‘, a mean 
reduction of 2.6 + 8.6 mg day- ‘. 
The adjusted mean _+SEM reductions in oral cortico- 
steroid dose from baseline to the last available dose 
recorded whilst receiving study treatment were 4.4_+ 1.0 
mg day-‘, 2.2+ 1.0 mg day-’ and 1.2_+ 1.0 mg day-’ for 
the FP 4 mg, FP 1 mg and placebo groups, respectively 
(Fig. 2). There was a significantly greater reduction in the 
FP 4 mg group compared with the placebo group 
(P=O.O04) and the FP 1 mg group (P=O.O39). No 
significant difference was found between FP 1 mg and 
placebo (P=O.400). 
The median percent reduction in daily oral steroid dose 
was 66.7% with FP 4 mg, 50.0% with FP 1 mg and 22.5% 
with placebo. There was a significantly greater reduction in 
694 J. WESTBROEK ETAL. 
TABLE 2. Effect of treatment on mean daily oral steroid dose 
Parameter FP4mg P-value vs. FP 1 mg 
day-’ phtcebo day-’ 
Mean -t SD prednisolone dose (mg day-‘) 
Baseline 10.3 + 5.8 9.5k5.6 
week 12 53f7.6 6.2k8.1 
Reduction in oral steroid use (mg day-‘) 5.Ok7.5 3.9+_8.3 
Adjusted mean +_SEM reduction (mg day-‘) 4-4kO.98 o-004 2-2*1-o 
Median reduction (%) 66.7 <O.OOl 50.0 
FP: fiuticasone propionate; SD: standard deviation; SEM: standard error of the mean. 
P-value vs. 
placebo 
0400 
0.259 
Placebo 
10*4+_ 5.9 
7.4+_ 7.8 
2.6k8.6 
1.2* 1.0 
22.5 
r 1 
+ * 
f 
J! i.a ow 
FP4mg FPlmg PhC&O 
FIG. 2. Oral steroid sparing effect of fluticasone 
propionate in patients with severe asthma over 12 weeks 
treatment. FP daily dose vs. reduction in oral steroid dose 
(mg day-‘). Values are presented as adjusted mean 
f WM.*: Significantly different from FP 1 mg (P = 0.039). 
t: Significantly different from placebo (P= 0.004). 
the FP 4 mg group compared with the piacebo group 
(P< O+IOI) and compared with the FP 1 mg group 
(P= 0.038). No significant difference was found between 
FP 1 mg and placebo (P = O-259). The number of patients 
who completed the study and entirely discontinued the use 
of oral steroids was 37 (37%) in the FP 4 mg group, 25 
(26%) in the FP 1 mg group (P = O-038 for FP 4 mg vs. FP 1 
mg) and 16 (18%) in the placebo group (P < O-00 1 for FP 4 
mg vs. placebo) (Fig. 3). 
DAILY PEF 
The mean &SD increases in morning PEF following 12 
weeks of treatment in the FP 4 mg, FP 1 mg and placebo 
groups were 27+52 mm-‘, 12+_53 min-’ and 12+42 
min-’ respectively (Table 3). There was a trend for greater 
improvement in favour of FP 4 mg versus placebo for 
morning PEF (PzO.053). The mean increases in evening 
PEF following 12 weeks of treatment in the FP 4 mg, FP 1 mg 
and placebo groups were 21+_56 1 min-‘, 6+45 1 min-’ 
and IO_+39 l/rain-‘, respectively. Evening PEF following 
treatment was significantly higher in the FP 4 mg group 
compared with the FP 1 mg group (P=O.OlO). There was a 
trend for greater improvement in favour of FP 4 mg versus 
placebo (P=O-060). 
cL.JMc LUNG FUNCTION 
Clinic PEF and FEVt increased in all three treatment 
groups during the study, but there was no significant 
differences between the treatments (Table 3). The mean 
increases in morning PEF following 12 weeks of treatment 
in the FP 4 mg, FP 1 mg and placebo groups were 24 f 78 1 
rain-’ ,7+631min-’ and 22+ 57 1 min-’ respectively. The 
mean increases in FEVt following 12 weeks of treatment in 
the FP 4 mg, FP 1 mg and placebo groups were 0.14 k 0.47 1, 
0.07 f0.34 1 and 0.06 f 0.38 1 respectively. 
SYMPTOM SCORES 
The results of the symptom scores are tabulated in Table 4. 
FP 4 mg resulted in a significantly higher percentage of days 
when the patients were free from daytime (P = 0.036) and 
night-time (P=O-021) wheeze compared with the placebo 
group, and a trend for a higher percentage of symptom-free 
nights (P=O-075) compared with the FP 1 mg group. The 
percentage of days when patients were free from daytime 
shortness of breath was sign&antly higher in the FP 4 mg 
group compared with the placebo (P= O-036). The percen- 
tage of nights when patients were not awoken due to 
asthma was significantly higher in the FP 4 mg compared 
with the placebo group (P = O-008) with a trend compared 
with the FP 1 mg (P = 0.053) group. 
Similar numbers of patients used the Sidestream (36 
37%), Pari LC plus (54-57%) and Cirrhus (69%) 
nebulizers in the three treatment groups (Table 5). In 
addition, similar numbers of patients used a mouth-piece 
(94-97%) and face-mask (36%). 
Statistical analyses were performed allowing for varia- 
tions due to the type of nebulizer in the model. No 
significant treatment interactions were seen between the 
efficacy and safety variables and use of different nebulizers. 
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FIG. 3. Cessation of oral steroid use. Fluticasone 
propionate dose vs. number of patients stopping 
prednisolone. Values are presented as number of patients 
(%) stopping presnisolone. Total number of patients in 
each group: FP 4 mg= 100, FP 1 mg=99, placebo =93. 
* Significantly different from FP 1 mg (P= 0.038). 
t Significantly different from placebo (PC 0.001). 
Safety 
ADVERSE EVENTS 
The overall incidence of adverse events was similar in all 
three treatment groups (79% of patients receiving FP 4 mg, 
76% of patients receiving FP 1 mg and 77% of patients 
receiving placebo). The most commonly reported adverse 
events were either respiratory in nature or predictable 
adverse events. The incidence of these adverse events 
differed between the groups (Table 4). More patients in 
the placebo (10%) and FP 1 mg (10%) groups had asthma 
exacerbations which were serious or resulted in the patients 
being withdrawn from the study than in the FP 4 mg (2%) 
group. There were more predictable adverse events in the 
FP 4 mg group than in the other two groups, although oral 
candidiasis was reported by more patients in the FP 1 mg 
group (14%) than the FP 4 mg group (12%) or placebo 
group (8%). A total of 32 patients withdrew from the study 
due to an adverse event; most of the withdrawals were due 
to an exacerbation of asthma. Fewer patients withdrew 
from the FP 4 mg group in which 5 (5%) withdrew due to 
an adverse event, compared with 1.5 (15%) patients in the 
FP 1 mg and 12 (13%) in the placebo group. The dilference 
between the numbers of patients who withdrew from the 
study were significant between FP 4 mg and FP 1 mg 
(P= 0.003) and FP 4 mg and placebo (P = 0.032). 
Serious adverse events during treatment were reported by 
a total of 28 patients (28%) six in the FP 4 mg group, nine 
in the FP 1 mg group and 13 in the placebo group. In each 
treatment group, the majority of events were related to 
respiratory conditions. Serious adverse events were con- 
sidered by the investigator to be drug related in only two 
patients, the first patient had been randomized to the 
placebo group and the second patient to the FP 1 mg 
group. Both patients had an asthma exacerbation which 
was assessed by the investigator as ‘possibly related’ to the 
study medication. One patient withdrew from the FP 4 mg 
group due to a serious adverse event compared with seven 
from the FP 1 mg group and six from the placebo group. 
Two patients died during the study. One patient, who 
had been receiving FP 4 mg, died during the post-treatment 
period after developing gastric bleeding, considered by the 
investigator to be unrelated to study ‘medication and the 
other patient, in the placebo group, developed status 
asthmaticus. 
LABORATORY RESULTS 
When all the samples were compared, the geometric mean 
(coefficient of variation (CV) %) concentrations at baseline 
were 192 (66%) mnol l-’ in the FP 4 mg group, 208 (48%) 
mol 1-i in the FP 1 mg group and 181 (56%) mnol 1-l 
in the placebo group. After 6 weeks of treatment, the 
mean values had decreased in all the groups, but after 
12 weeks of treatment the mean values had decreased to 164 
(72%) mol 1-l in the FP 4 mg group, decreased to 205 
(49%) nmol 1-l in the FP 1 mg group and increased to 
TABLE 3. Mean & SD lung function results before (BL) and after (Post-Rx) 12 weeks of treatment 
Lung function 
parameter 
FP4mg P-value FP 1 mg P-value Placebo P-value 
FP 4 mg vs. FP 1 mg YS. FP4mg 
BL Post-Rx placebo BL Post-Rx placebo BL Post-Rx vs. 1 mg 
Diary card PEF 
am PEF 
(1 min-‘) 252* 101 281+ 108 P=O.O53 273 k 94 291 f 101 P=O.765 256+87 272_+86 P=O.O99 
pm PEF 
(1 min-‘) 276+ 102 299f 104 P=O.O60 302+ 101 310+104 P=O.497 280+89 295+88 P=O.OOl 
Clinic lung function 
am PEF 
(1 mm-‘) 272+ 107 297k 112 P=O.350 293_+105 307+114 P=O.821 2735 100 300_+96 P=O.233 
FEVdL) 1.57kO.70 1.71kO.71 P=O.261 1.63kO.75 1.71+_0.80 P=O.711 1.49kO.64 1.62kO.74 P=O.465 
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TABLE 4. Symptom scores (median percentage symptom free days/nights) following treatment 
P-value P-value P-value 
FP 4 mg vs. FP 1 mg vs. FP 4 mg vs. 
Symptom FP4mg placebo FP 1 mg placebo Placebo FP 1 mg 
Cough CD> 
(N) 
Chest tightness (D) 
(N) 
Wheeze 03 
0 
Shortness CD) 
of breath 8 
Nights not awoken 
by symptoms (%) 
FP: fluticasone propionate 
D: day 
N: night 
65% 0.536 66% 0.542 60% 0.994 
73% 0.559 67% 0.516 70% 0.931 
84% 0.150 78% 0.878 76% 0.313 
85% 0.225 70% 0.869 75% 0.284 
78% 0.036 49% 0.690 56% 0.136 
70% 0.021 73% 0.551 70% 0.075 
58% 0.036 34% 0.933 25% 0.094 
70% 0.114 58% 0.936 50% 0.203 
87% 0.008 74% 0.752 64% 0.053 
TABLE 5. Nebulizer use in three treatment groups 
Number (%) of patients 
Placebo FP 1 mg FP4mg 
Number of patients 
Nebulizer 
Pari LC plus/Pari Boy 
Sidestream/Portaneb 
Cirrus/DeVilbiss 
Face-mask 
Mouth-piece 
96 102 103 
55(57%) 56(55%) 56(54%) 
35(36%) 38(37%) 38(37%) 
6(6%) S(S%) 9(9%) 
3(3%) 6(6%) 3(3%) 
93(94%) 96(94%) 100(97%) 
200 (47%) nmol 1-l in the placebo group. After 6 weeks of 
treatment, there were no significant differences between the 
treatments. Following 12 weeks of treatment, the adjusted 
mean serum cortisol value was significantly lower in the FP 
4 mg group compared with the placebo group (P= 0.036). 
A similar pattern of serum cortisol changes was seen for 
samples collected between 08:OO to 1O:OO h. The geometric 
mean cortisol values in the patients who stopped taking 
oral steroids at the beginning and end of treatment, 
respectively, were: 216 (59.1%) nmol 1-l and 221 (55.4%) 
nmol 1-t in the FP 4 mg group, 238 (39.7%) nmol 1-l and 
283 (29.3%)’ mu01 1-l in the FP 1 mg group and 179 
(52.7%) nmoll-’ and 207 (46.4%) nmol 1-t in the placebo 
group. There were no significant differences between the 
three treatment groups. Only eight (8.0%) patients in FP 4 
mg group had serum cortisols that were below the threshold 
value at the end of treatment, compared with six (7.0%) in 
the placebo group. No clinical effects related to changes in 
serum cortisol values were seen in any of the patients. 
Discussion 
The primary aim of this study was to compare the efficacy 
and safety of nebulized FP 4 mg day- ’ and 1 mg day- ’ 
with placebo in the reduction of oral steroids required in 
adult patients with chronic oral steroid dependent asthma, 
while maintaining asthma stability. Patients, whose asthma 
was in a stable phase such that they had not had an asthma 
exacerbation during the previous month, gradually tried to 
substitute the oral portion of their corticosteroid therapy 
with nebulized treatment. Patients must have required 
continuous oral steroid therapy for 3 months before 
entering the study and for 6 of the previous 12 months in 
order to be eligible, thereby establishing their dependence 
on oral steroids. At the end of the 12 weeks of treatment 
there was a significant dose-related reduction in oral steroid 
requirements, with a rank order of FP 4 mg > Fp 1 mg > 
placebo. Significantly more patients receiving FP 4 mg were 
also able to discontinue their need for oral steroid 
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completely compared with the other two groups, confirm- 
ing the value of nebulized FP as an effective replacement 
therapy for oral steroid. This result supports the findings of 
Noonan et al. (14) who demonstrated a significant dose- 
related reduction in oral steroid requirements in patients 
with oral steroid dependent asthma treated with FP 
1.5 mg day-’ and 2.0 mg day- ’ by a metered dose inhaler. 
Clinic lung function measured by PEF and FEV, 
improved in all three groups over the 12 week treatment 
period, but was best in the FP 4 mg group, although the 
differences between the groups were not significant. The 
diary card PEF results showed a greater separation of the 
doses, such that after 12 weeks of treatment, the difference 
in improvement between the FP 4 mg and placebo groups 
was statistically significant for evening PEF and ap- 
proached significance for morning PEF. The study was 
designed to maintain control of the patients’ asthma whilst 
they reduced their daily dose of oral steroid. In fact, if 
anything, the patients’ lung function tended to improve, in 
a dose-related manner, suggesting improved disease con- 
trol, despite a significant reduction in oral steroid require- 
ments. In addition, there were more withdrawals in the 
placebo group due to exacerbations compared with the FP 
4 mg group, leaving fewer more severely affected patients in 
the placebo group at the end of the study. These 
withdrawals from the placebo group may have biased the 
results on lung function, as well as on the other efficacy 
parameters, against the active treatment. 
In addition to the improvements in lung function seen 
during FP treatment, patients showed significant improve- 
ments in their symptom scores recorded in diary cards. 
Patients receiving FP 4 mg had significantly fewer days and 
nights with wheeze, significantly fewer days with shortness 
of breath and significantly more nights when they were not 
woken by their asthma, than patients receiving placebo. 
These improvements in symptoms support those seen in 
objective measures of lung function and support a clinically 
meaningful benefit of nebulized FP in these patients. 
By contrast with the results from this double-blind, 
placebo-controlled study in a large number of patients, the 
oral steroid sparing effect of nebulized budesonide has been 
studied in two small, uncontrolled studies. In the first study, 
42 adults with chronic oral steroid dependent asthma 
received 12 weeks of treatment with nebulized budesonide 2 
mg day -’ in an open study (17). At the end of this period, 
23 patients (55%) were able to reduce their oral steroid 
requirement significantly (mean reduction of 59% from 
initial dose of 12.3 mg) while maintaining their lung 
function. None was able to discontinue their oral steroids 
completely. In the second open study, which used higher 
doses of nebulized budesonide (between 4 and 8 mg daily) 
over a longer treatment period (up to 18 months), 14 (78%) 
patients successfully stopped oral steroids, while maintain- 
ing their lung function (4). These data support the findings 
of the present large, placebo-controlled study with 
nebulized FP and suggest a role for nebulized steroids in 
the treatment of oral steroid dependent patients with 
asthma. 
Three different nebulizers (i.e. Sidestream/Portaneb 50, 
Pari LC pIus/Pari-Boy and Cirrus/ DeVilbiss: Pulmo-Aide) 
commonly used in Europe, were utilized in the study. All 
were found to work effectively with FP Nebules producing 
respirable aerosols, with good output of drug and similar 
mass median aerodynamic diameters. The use of different 
nebulizers did not significantly inffuence the effect of 
treatment on primary efficacy or cortisol values, confirming 
the clinical effectiveness of all three nebulizers with FP 
Nebules in this patient population. 
After randomization, 52 patients were withdrawn from 
the study. Most of these patients were withdrawn due to an 
adverse event, generally related to a lower respiratory tract 
condition. Significantly fewer patients were withdrawn 
from the FP 4 mg group than from either of the other 
two groups, indicating better overall disease control and in 
line with the greater improvements in lung function and 
symptoms in this group. 
Nebulized FP 1 mg and 4 mg daily were as well tolerated 
as placebo throughout the study. The overall incidence of 
adverse events was similar in all the treatment groups, and 
those which were reported most commonly were of a 
respiratory nature or were predictable adverse events. The 
most common predictable adverse event was candidiasis of 
the mouth or throat. This was reported by 12% of patients 
in the FP 4 mg group, 14% in the FP 1 mg group and 8% in 
the placebo group, and these frequencies of candidiasis are 
anticipated in oral corticosteroid dependent patients on 
high doses of inhaled steroids (18). Serious adverse events 
during treatment were reported by 28 patients, 13 (14%) in 
the placebo group, nine (9%) in the FP 1 mg group and six 
(6%) in the FP 4 mg group. In the majority of these patients 
a respiratory adverse event was reported, suggesting a dose- 
related trend for improvement in control of the patients’ 
asthma by nebulized FP. 
The mean serum cortisol values for the patients in all 
three treatment groups were at the lower end of the normal 
range at the start of treatment, consistent with the use of 
regular oral steroids, in many cases, for a number of years. 
After 12 weeks of treatment the mean cortisol value in the 
FP 4 mg group was lower than in the placebo and FP 1 mg 
groups, but remained within the normal range, despite 
being at the lower end of the normal range at the start of 
treatment. There were no clinical signs or symptoms or 
laboratory abnormalities associated with this fall in serum 
cortisol and its clinical importance is doubtful. In addition, 
in the patients who were able to stop taking oral steroids on 
account of treatment with nebulized FP (4 mg and 1 mg), 
serum cortisol levels did not fall but tended to increase. The 
continuing need for higher doses of oral steroids as opposed 
to inhaled steroids, seen in the placebo group, would be 
likely to result in other clinically important systemic side 
effects, such as reduction in bone density and thinning of 
the skin, were this to continue long term (19). Relevant to 
this, a recent prospective, double-blind, placebo-controlled, 
multicentre study, demonstrated that FP 1 mg day- ’ via an 
MD1 had no effect on bone density over a 2 year treatment 
period (20). 
One potential complicating factor in the interpretation of 
the serum cortisol values between the three groups is the 
recognised cross-reactivity of prednisolone (up to 24%) in 
the immunoassay used to measure cortisol in this study 
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(TDx CortisolTM fluorescence polarisation immunoassay: 
Abbott Laboratories, Abbott park, Illinois, U.S.A.). It is 
possible that the higher dose of oral prednisolone required 
by the placebo group may have spuriously raised the 
measured cortisol value in this group and thereby 
accentuated any apparent di%mnce between the placebo 
and FP treatment groups. 
In conclusion, this large, placebo-controlled study 
comparing nebulized FP 2 mg b.d. FP 0.5 mg b.d. and 
placebo-over 12 weeks of treatment, demonstrated that the 
use of FP Nebulesm was associated with a significant 
reduction in oral prednisolone requirement in patients with 
oral corticosteroid dependant asthma. After 12 weeks of 
treatment there was a dose-related reduction in oral 
corticosteroid use, with 37% of patients in the FP 2 mg 
b.d. group being able to stop their oral steroids completely. 
FP Nebules’I” at a daily dose between 1 mg and 4 mg are a 
safe and effective means of reducing the oral corticosteroid 
requirement of dependent patients with severe chronic 
asthma. 
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